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Background: Nur77 is an orphan nuclear receptor expressed in human atheroma. In vascular cells in vitro, Nur77
expression is induced by pro-inflammatory factors, such as oxidized LDL (oxLDL).
Methods: We analyze the role of Nur77 in the oxLDL-induced differentiation of macrophages into dendritic cells
(DC). The murine RAW264.7 macrophage cell line was stably transfected with expression plasmids encoding
either GFP or GFP fusions with either full-length Nur77 (GFP-Nur77), Nur77 lacking the DNA binding domain
(GFP-Nur77-ΔDBD) or Nur77 lacking the transactivation domain (GFP-Nur77-ΔTAD).
Results: GFP-Nur77 overexpression significantly suppressed the effect of oxLDL treatment on DC morphologic
changes, expression of DC maturation markers, endocytic activity, allogeneic activation of T cell proliferation, and
the activity and secretion of pro-inflammatory cytokines. Analysis of GFP-Nur77-ΔTAD and GFP-Nur77-ΔDBD indicated
that the Nur77 DNA binding and transactivation domains were both required for this effect. GFP-Nur77-ΔDBD
consistently had the opposite effect to GFP-Nur77, increasing DC-type differentiation in all assays. Interestingly,
GFP-Nur77-ΔDBD protein was cytosolic, whereas GFP-Nur77 and GFP-Nur77-ΔTAD were both nuclear.
Conclusions: These data show that GFP-Nur77 inhibited differentiation of oxLDL-treated macrophages into DC.
The effects of Nur77 on the macrophage phenotype may involve changes in its subcellular distribution.
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Atherosclerosis is a chronic inflammatory disease of the
arterial wall. From the first appearance of fatty streaks
through to the development of advanced atheromatous
plaques, atherosclerosis involves interactions between the
immune system and metabolic risk factors. The immune
and inflammatory actions of monocytes/macrophages play
an important role in this disease [1-3]. Peripheral blood
monocytes enter the arterial tunica intima, where they
differentiate into macrophages or immature dendritic
cells (DC) that differentiate fully after exposure to envir-
onmental factors [4]. We have shown in vitro that oxi-
dized low-density lipoprotein (oxLDL) stimulates mature* Correspondence: rjshenlinghong@126.com; rjheben@126.com
†Equal contributors
Department of Cardiology, Renji Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai 200127, People’s Republic of China
© 2014 Hu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.macrophages to differentiate into DC [5], a process that
might be important for inflammatory and immune re-
sponses within the atheroma. Although there is currently
no in vivo evidence for macrophage–DC differentiation,
the functional consequences of this event might signifi-
cantly exacerbate inflammation in the atheroma. The
molecular mechanisms underlying macrophage–DC dif-
ferentiation is essential for our understanding of athero-
genesis and the development of novel drug therapies.
The orphan nuclear receptor Nur77, also known as
NR4A1, NGFI-B or TR3, is a member of the steroid/thy-
roid hormone nuclear receptor superfamily, and was first
identified as an early response gene to growth factor
stimulation. These nuclear receptors are all transcription
factors characterized by three main functional domains:This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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amino-terminal transactivation domain, and a carboxy-
terminal hetero-dimerization and ligand binding domain.
Nur77 is an orphan receptor since no specific ligands
have been identified. Previous studies have identified di-
verse roles for Nur77 in cell proliferation, differentiation
and apoptosis, as well as neuroendocrine regulation,
neurological disorders, liver regeneration and cancer.
Nur77 is expressed in human atherosclerotic lesions,
and can be induced in human smooth muscle cells, mac-
rophages and endothelial cells [6,7]. Pei LM et al. [8]
found that many inflammatory stimuli, including oxLDL,
elevate expression of Nur77 in macrophages in vitro,
and we have found that Nur77 is upregulated in macro-
phages exposed to oxLDL [5].
Here, we have used in vitro approaches to investigate a
possible role for Nur77 in oxLDL-induced macrophage–
DC differentiation. We show that overexpression of
Nur77 significantly inhibited the differentiation into DC
of the RAW264.7 macrophage cells exposed to oxLDL.
Analysis of deletion mutants of Nur77 indicated that the
Nur77 DNA binding and transactivation domains were
both required for this suppressive effect.Results
Establishment of stable RAW264.7 cell lines expressing
GFP-Nur77 and GFP-Nur77 deletion mutants
We have shown previously that macrophages exposed to
oxLDL in vitro differentiate into mature DC. Here, we
have investigated a possible role for the orphan nuclear
receptor Nur77 on the differentiation of oxLDL-treated
RAW264.7 cells, a murine macrophage cell line. Nur77,
a steroid/thyroid hormone nuclear receptor superfamily,
contains three characteristic functional domains involved
in transactivation, DNA binding, and ligand binding
(Figure 1A). We established clonal RAW264.7 cell lines
stably expressing either wild-type GFP-Nur77 or GFP
fusion proteins with Nur77 lacking either the transacti-
vation or DNA binding domains (GFP-Nur77-ΔTAD
and GFP-Nur77-ΔDBD, respectively). GFP-Nur77 ex-
pression was 3–4 fold the level of endogenous Nur77
(Figure 1B). The two deletion mutants of Nur77 were
expressed to similar extents (Figure 1C). Fluorescent
microscopy revealed that GFP-Nur77-ΔDBD was cyto-
solic, whereas GFP-Nur77 and GFP-Nur77-ΔTAD were
strictly nuclear (Figure 1D) suggesting that DNA bind-
ing is required for nuclear localization.Nur77 inhibits the differentiation of oxLDL-treated
RAW264.7 cells
We tested the effects of oxLDL on the morphology, DC
surface marker expression, endocytic activity, allostimu-
latory activity, and cytokine secretion of the RAW264.7stable cell lines. Consistent with previous results, 72.50%
of GFP control cells had DC morphology after oxLDL
treatment as determined by increased cell size, the
presence of multiple prominent cytoplasmic processes,
and prominent nucleoli (Figure 2A and B). In contrast,
although most GFP-Nur77-expressing cells increased
in size, only 28.94% had DC morphology following
oxLDL treatment. In contrast, 72.30% oxLDL-treated
GFP-Nur77-ΔTAD or 82.8% of oxLDL-treated GFP-
Nur77-ΔDBD cell lines were of DC morphology, which
was similar to control GFP-expressing cells (p >0.05).
There was a small but statistically significant increase
in the proportion of DCs in GFP-Nur77-ΔDBD cells
compared to GFP-expressing cells (p <0.05; Figure 2A,B).
To determine whether endogenous Nur77 played a role in
macrophage–DC differentiation, we used siRNAs to de-
plete Nur77 and assayed the effect on oxLDL-induced
morphological changes. Transfection of Nur77 siRNA
successfully depleted endogenous Nur77 in RAW264.7
cells compared to the scrambled siRNA (Figure 2C) and
led to a 17% increase in the proportion of cells with DC
morphology following oxLDL treatment compared to that
in the scrambled siRNA group ( 66.5 ± 12.4% vs. 83.8 ±
12.1%, p <0.05; Figure 2D,E).
To provide definitive evidence to the observed morph-
ology, CD209 was tested by confocal microscopy. (De-
tailed descriptions of the materials and experimental
methods are available in Additional files 1 and 2).Nur77 inhibits phenotypic changes in oxLDL-treated
RAW264.7 cells
The changes in cell morphology described above suggest
that Nur77 inhibits oxLDL-induced RAW264.7 cell dif-
ferentiation into DCs through its DNA binding and
transactivation domains. To investigate this possibility,
we evaluated phenotypic changes in oxLDL-treated
RAW264.7 cells stably expressing Nur77 and Nur77 mu-
tant proteins by flow cytometry using specific antibodies
against co-stimulatory molecules, antigen-presenting mol-
ecules, and markers of DC activation. Following oxLDL
treatment, the levels of CD40, CD86, CD83, MHC class II,
and CD1d were reduced by 62.4%, 44.69%, 51.7%, 55.2%,
and 53.29%, respectively, in RAW264.7 cells stably ex-
pressing GFP-Nur77 protein compared with those in
GFP-expressing cells. However, there was little difference
in the levels of these proteins when comparing cells ex-
pressing either GFP-Nur77-ΔTAD or GFP-Nur77-ΔDBD
with GFP-expressing cells, with the exception that GFP-
Nur77-ΔDBD cells had a small but significant increase in
the expression of CD83, MHC class II molecules, and
CD1d (p <0.05 compared to control cells; Figure 3A).
Moreover, all of the aforementioned proteins were signifi-




Figure 1 Characterization of stable RAW264.7 cell lines expressing Nur77 and Nur77 deletion mutants. (A) Schematic structure of the
Nur77 gene and deletion mutants lacking either the transactivation domain (TAD) or DNA binding domain (DBD). (B) Expression of Nur77 protein in
untransfected RAW264.7 cells and in RAW264.7 cell lines expressing GFP or GFP-Nur77. Expression of GFP-Nur77 is 3–4-fold higher than endogenous
Nur77 in untransfected or GFP-transfected cells. (C) Expression of GFP-Nur77-ΔTAD and GFP-Nur77-ΔDBD fusion proteins in stably transfected
RAW264.7 cells. β-actin expression was used to control for protein loading. A representative of three separate experiments is shown. (D) Subcellular
localization of GFP-Nur77, GFP-Nur77-ΔTAD, and GFP-Nur77-ΔDBD in RAW264.7 cells.
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bled siRNA (p <0.05; Figure 3B).Nur77 decreased endocytosis in oxLDL-treated RAW264.7
cells
We have previously shown that oxLDL-treated RAW264.7
cells gain several of the functional characteristics of ma-
ture DC [5]. Therefore, we next assayed the role of Nur77
in these oxLDL-induced functional changes. Using LY up-
take as a marker of endocytosis (Figure 4A), we found that
a large proportion of the four stable RAW264.7 cell lines
were LY + following 12 h exposure to oxLDL. Consistent
with published results, oxLDL had a dynamic effect on
endocytosis. GFP-expressing controlcells exhibited de-
creased LY uptake by approximately 33% at 24 h and
57% at 48 h after oxLDL treatment. Similar results were
obtained from GFP-Nur77-ΔTAD and GFP-Nur77-
ΔDBD-expressing cells, except that at 48 h LY uptake
by GFP-Nur77-ΔDBD-expressing cells was 15% lower
than GFP-expressing cells. In contrast, oxLDL had little
effect on LY uptake in GFP-Nur77-expressing cells at ei-
ther 24 h or 48 h. These results indicate that overexpres-
sion of Nur77 protein in RAW264.7 cells inhibited the
endocytic changes typically displayed by mature DCs, andthat this inhibition was dependent upon the DNA binding
and transactivation domains of Nur77.Nur77 reduced the stimulatory effect of oxLDL-treated
RAW264.7 cells on T cell proliferation
Stimulation of allogeneic T cell proliferation is an im-
portant function of mature DC. Therefore, we evaluated
the effect of Nur77 on T cell proliferation. RAW264.7
cells stably expressing either Nur77 or the Nur77 mu-
tant proteins were pretreated with 10 μg/ml oxLDL for
48 hrs and then cultured with T cells at a ratio of 1:10
for 5 days. To detect T cell proliferation, we monitored
BrdU incorporation as a measure of cells entering S
phase. In the absence of oxLDL, there was no T cell pro-
liferation in any of the four stable cell lines. OxLDL-
treated GFP-expressing control cells effectively induced
the proliferation of T cells, as did GFP-Nur77-ΔTAD-
expressing and GFP-Nur77-ΔDBD-expressing cells. In
contrast, T cell proliferation in co-cultures with GFP-
Nur77-expressing cells was approximately one third of
the other cell lines (Figure 4B). These results are consist-
ent with an inhibitory role for Nur77 in this T cell assay,




Figure 2 Nur77 inhibits DC morphological changes in oxLDL-treated RAW264.7 cells. (A) RAW264.7 cells stably expressing GFP-Nur77,
GFP-Nur77-ΔTAD, or GFP-Nur77-ΔDBD were treated with oxLDL (10 μg/ml) for 48 h and visualized by phase contrast microscopy (400×). Results
are representative of three separate experiments. (B) Cells with DC morphology were calculated as the percentage of all cells observed in 10
different fields at 400× magnification. The bars represent mean ± SD from three experiments. *p <0.05 compared with GFP-expressing control.
(C) Western blots showing endogenous Nur77 in RAW264.7 cells 48 h after transfection with either scrambled siRNA or Nur77 siRNA. Similar results
were obtained in three separate experiments. (D) Phase contrast images showing the morphology of oxLDL-treated RAW264.7 cells transfected with
either scramble siRNA or Nur77 siRNA. Cultured cells were visualized by phase contrast microscopy as described in (A) and cells with DC morphology
were calculated as described in (B). (E) *p <0.05 compared with scrambled control.
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RAW264.7 cells
Finally, we assayed the effect of Nur77 on cytokine se-
cretion by oxLDL-treated RAW264.7 cells. Here we
show that, IL-12 and TNF-α from oxLDL-treated GFP-
Nur77 cells were decreased to 46.8% and 41.5%, respect-
ively, compared with that from GFP-expressing controlcells. In contrast, expression of the Nur77 mutant pro-
teins did not decrease oxLDL-induced IL-12 and TNF-α
secretion. GFP-Nur77-ΔDBD-expressing cells demon-
strated a 24.9% and 12.7% increase in IL-12 and TNF-α
secretion, respectively (Figure 5A,C). These data show
that Nur77 had an inhibitory effect on cytokine secre-
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Figure 3 Flow cytometry analysis of the cell surface phenotype of oxLDL-treated RAW264.7 cell lines. (A) Expression of CD40, CD86, CD83,
MHC Class II, and CD1d in RAW264.7 cells lines treated with oxLDL for 48 h. Mean ± SD of three independent experiments is shown. *p <0.05
compared with GFP-expressing control. (B) Expression of CD40, CD86, CD83, MHC Class II, and CD1d in RAW264.7 cells transfected with either
scrambled siRNA or Nur77 siRNA and stimulated with oxLDL for 48 h. *p <0.05 compared with scrambled control.
Hu et al. BMC Immunology 2014, 15:54 Page 5 of 10
http://www.biomedcentral.com/1471-2172/15/54and transactivation domains. To test the ability of pro-
ducing several cytokines by these cells, we also analyzed
TNF-α and IL-12 including a stimulated control with
LPS in GFP-expressing control cells. Results showed that
both of the two cytokines can be stimulated by LPS and
the levels were 3-fold higher than by the stimulation
with oxLDL (TNF-α: 490.12 ± 14.14 vs. 125.60 ± 7.07 ng/ml;
IL-12: 15.47 ± 0.28 vs. 4.15 ± 0.21 pg/ml ) (Figure 5B,D).Discussion
Dendritic cells are the most potent of all antigen-
presenting cells, and play a key role in vascular inflamma-
tion and immune activation [9]. OxLDL is a particularly
potent inducer of inflammation during the development
of atherosclerosis [10,11]. Here, we have shown that
Nur77 is likely to play an inhibitory role in DC differ-
entiation. We found that overexpression of Nur77 in a






















































Figure 4 Nur77 enhanced the endocytic activity but suppressed the DNA synthesis of RAW264.7 treated by oxLDL. (A) Flow cytometry
analysis of endocytic activity using lucifer yellow (LY) uptake by oxLDL-treated RAW264.7 cells stably expressing GFP-Nur77, GFP-Nur77-ΔTAD, or
GFP-Nur77-ΔDBD. Mean ± SD of three independent experiments is shown. *p <0.05 compared with GFP-expressing control. (B) Flow cytometry
analysis of BrdU incorporation by co-cultures of allogeneic T cells and RAW264.7 cells stably expressing either GFP, GFP-Nur77, GFP-Nur77-ΔTAD,
or GFP-Nur77-ΔDBD. Mean ± SD of three independent experiments is shown. *p <0.05 compared with GFP-expressing control.
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ation into mature DCs following oxLDL treatment,
whereas siRNA-mediated Nur77 depletion had the op-
posite effect. Consistent with this, constitutive expression
of Nur77 in vivo decreases immune cell development and
maturation. Together, these data suggest that endogenous
Nur77 may have an inhibitory effect on macrophage acti-
vation and immunity. Many studies of vascular cells also
suggest a protective role for Nur77 in atherogenesis
[12-14]. For example, overexpression of Nur77 in arterial
smooth muscle reduces the formation of smooth muscle-
rich lesions [13]. In addition, in vitro assays have dem-
onstrated that Nur77 significantly reduces the inflamma-
tory response and lipid-loading of human macrophages
[15,16].The possible role of Nur77 in endothelial cells re-
mains unclear, however. In human vascular endothelial
cells, Nur77 mediates cell cycle arrest through up-
regulation of p27Kip1 and downregulation of cyclin A
[17], whereas others have implicated Nur77 in vascular
endothelial growth factor (VEGF)-A-induced angiogen-
esis [18,19]. Thus, the role of Nur77 in human endothe-
lial cell proliferation is controversial. The reasons for
these contradictory effects on endothelial cell prolifera-
tion are not clear, but similar effects of Nur77 are ob-
served in other cells. For example, Nur77 was originally
recognized for its role in cancer cell proliferation
[20-22] but was later found to be a potent pro-
apoptotic molecule [23,24]. Extensive evidence indi-













































































Figure 5 Nur77 overexpression in RAW264.7 cells reduces oxLDL-induced inflammatory cytokine synthesis. Sandwich ELISA analysis of
TNF-α (A) and IL-12 (C) for the supernatants of oxLDL-treated RAW264.7 cells stably expressing GFP, GFP-Nur77, GFP-Nur77-ΔTAD or GFP-Nur77-
ΔDBD. Data represent mean ± SD of three independent experiments for 1 × 106 cells, *p <0.05 compared with GFP-expressing control cell.
(B) and (D) showed the level of TNF-α and IL-12 in GFP-expressing control cells with or without stimulated by oxLDL or LPS, respectively. The bars
represent mean ± SD from three experiments. *p <0.05 compared with control cells.
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the DNA binding and transactivation domains were
both required [25]. We have also found that the tran-
scriptional activity of Nur77 is required for suppression
of macrophage activation [16]. Thus, we were inter-
ested in whether the inhibitory effect of Nur77 on
oxLDL-induced macrophage differentiation was also
dependent upon its transcriptional activity. Consistent
with this, expression of GFP-Nur77ΔTAD had no sig-
nificant effect on the induction of DC differentiation by
oxLDL compared with expression of GFP alone. In con-
trast, expression of GFP-Nur77-ΔDBD caused a modest
but significant increase in the proportion of cells with
DC morphology and functionality.
The subcellular distribution of the GFP-Nur77 fusion
proteins is consistent with a transcriptional role for
Nur77 because GFP-Nur77-ΔDBD was mainly cytosolic,
whereas GFP-Nur77 and GFP-Nur77-ΔTAD were nu-
clear. These observations suggest that Nur77 proteinmay induce the differentiation of macrophages into DC
when it is localized in the cytosol. Although it is not
known if oxLDL induces the nuclear export of Nur77 in
macrophages, there is evidence from cancer cells that
Nur77 can be induced to translocate from the nucleus
to the cytosol and that this confers important biological
functions, including apoptosis and differentiation.Conclusion
the differentiation of macrophages into DC following ex-
posure to oxLDL can be suppressed by the transcriptional
activity of Nur77. The effect of Nur77 on macrophage
differentiation may be related to changes in its subcel-
lular location. Nur77 might induce macrophage-DC dif-
ferentiation when it localized in the cytosol. Further
studies are needed to understand the relationship between
the subcellular location of Nur77 and its protective effect
against atherosclerosis.
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Lipoprotein isolation and oxidation
LDL (d = 1.019–1.063) was isolated by sequential ultra-
centrifugation of EDTA-anticoagulated fasting plasma
from healthy normo-lipidemic volunteers. After ultra-
centrifugation, EDTA was dialyzed at 4°C against PBS
containing 0.5 mM EDTA. The LDL protein concentra-
tion was determined by a modification of the Lowry
method, using bovine albumin as the standard. Isolated
LDL (1 mg/ml) was oxidized at 37°C for 18 h in PBS
containing 5 μM CuSO4. Oxidation reactions were ter-
minated by the addition of EDTA (0.3 mM, pH 8.5) and
butylated hydroxytoluene (40 μM). Modified LDL was
dialyzed extensively at 4°C against PBS containing 0.5 mM
EDTA, and the oxLDL preparations were sterilized by
membrane filtration (0.45 μm) and stored in the dark at
4°C. All lipoprotein preparations were tested for endo-
toxin using an endotoxin assay kit (Sigma, St. Louis, MO).
The study protocol were approved by the Ethics Com-
mittee of Renji Hospital, School of Medicine, Shanghai
Jiao tong University and complied with the National
Regulations on the Use of Clinical Samples in China.
These volunteers provided written informed consent to
Ethics Committee for research purpose.
Cell culture
RAW264.7 cells were obtained from the American Type
Culture Collection, and grown at 37°C, 5% CO2 in
DMEM containing penicillin (100 U/ml), streptomycin
(100 μg/ml), and 10% heat-inactivated fetal calf serum.
Plasmid and transient transfection of RAW264.7 cells
The GFP-Nur77 expression plasmid (pGFP-Nur77), GFP-
Nur77-ΔTAD and GFP-Nur77-ΔDBD were gifts from
X-K. Zhang (Burnham Institute, La Jolla, CA). RAW264.7
cells were plated into 6-well plates, 1 × 106 cells per well,
incubated overnight, then transfected with Lipofectamine
2000 (Invitrogen, USA) and 7.5 μg DNA per well, accord-
ing to the manufacturer’s instructions.
Establishment of stable clones expressing GFP-Nur77,
GFP-Nur77-ΔTAD, and GFP-Nur77-ΔDBD
pGFP-Nur77, pGFP-Nur77-ΔTAD, pGFP-Nur77-ΔDBD,
and the pGFP-control vectors were introduced into
RAW264.7 cells as described [5]. Transfected cells were
allowed to recover for 24 h, followed by drug selection
using 500 μg/ml G418 for a week. Single cell clones were
identified by serial dilution in 96 well plates. Clonal
RAW264.7 cell lines stably transfected with pGFP-Nur77,
pGFP-Nur77-ΔTAD, pGFP-Nur77-ΔDBD or pGFP vec-
tors were incubated in medium containing 200 μg/
ml G418. Overexpression of GFP-Nur77, GFP-Nur77-
ΔTAD and GFP-Nur77-ΔDBD were confirmed by fluores-
cent microscopy and western blot analysis.siRNA transfections
The following small interfering RNAs (siRNAs; Dharmacon
Research Inc.) were used: Nur77, 5’-CAG UCC AGC
CAU GCU CCU C dTdT-3’; scrambled siRNA, 5’-GCG
CGC TTT GTA GGA TTC G dTdT-3’. siRNAs were
transfected (10-μl aliquot of 20 μM siRNA/well) into indi-
vidual wells of 6-well plates using Oligofectamine (Invitro-
gen), according to the manufacturer’s protocol. Two days
after transfection, cells were harvested for analysis.
Western blotting
Cells were lysed in 150 mM NaCl, 10 mM Tris (pH 7.5),
5 mM EDTA, 1% Triton X-100, 1 mM PMSF, 10 mg/ml
leupeptin, 10 mg/ml pepstatin, and 10 mg/ml aprotinin
for 30 min on ice. Equal amounts of lysates (50 μg) were
separated by 8–12% SDS-PAGE and transferred onto
Immobilon-P transfer membranes (Millipore, Billerica,
MA). Non-specific binding sites were blocked by incu-
bating membranes in 5% (w/v) solution of nonfat dried
milk in TBST (50 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 0.1% Tween 20). Blocked membranes were probed
with specific antibodies against Nur77 (1;1000, Abcam,
Cambridge, UK), GFP (1;1000, eBioscience, San Diego,
CA), or β-actin (1;5000, BioVision, Mountain View, CA)
in TBST. Membranes were washed 3 times with TBST
and then incubated for 2 h at room temperature in
TBST containing HRP-linked anti-rabbit or anti-mouse
immunoglobulin. After 3 washes in TBST, HRP was visual-
ized by chemiluminescence using the ECL kit (Chemicon,
Temecula, CA). The protein concentration was quanti-
fied using the BCA protein assay (Merck, Darmstadt,
Germany).
Phenotypic analysis by flow cytometry
Cells were incubated for 30 min with Phycoerythrin (PE)-
labeled monoclonal antibodies recognizing either CD40,
CD83, CD86, MHC Class II, or CD1d (eBioscience),
washed with staining buffer, and analyzed by flow cy-
tometry on a FACSCalibur (BD Biosciences, Franklin
Lakes, NJ).
Analysis of endocytic activity
Endocytosis was measured after treatment with oxLDL
(10 μg/ml) for the indicated times. Cells were incubated
at 37°C for 30 min with Lucifer Yellow (LY; 1 mg/ml;
Sigma-Aldrich), and washed 3 times at 4°C with cold
PBS containing 1% BSA and 0.05% NaN3. Cells were an-
alyzed on a FACSCalibur (BD Biosciences).
T cell proliferation assay
The effect on allogeneic T cell proliferation of oxLDL-
treated RAW264.7 cells was measured as described [13].
Briefly, T cells were purified from the spleens of C57BL/
6 mice using nylon wool columns. RAW264.7 cells
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oxLDL for 48 h and then treated with mitomycin C
(50 μg/ml) for 1 h. Afterwards, a total of 1 × 105 T cells
were added as responders. The cell mixtures were cultured
for 5 days and 20 μl diluted BrdU was added 18 h prior to
the end of the incubation period according to the proced-
ure recommended by the manufacturer (Chemicon). The
plates were analyzed using a spectrophotometer micro-
plate reader with the absorbance set at 450 nm (MK3,
Thermo, USA).
Cytokine assays
GFP-expressing RAW264.7 cells were stimulated by LPS
(5 μg/ml, Sigma) or oxLDL (10 μg/ml) for 24 h, and se-
cretion of IL-12 or TNF-α into the supernatant was ana-
lyzed using cytokine specific ELISA kits according to
manufacturer instructions (BD Bioscience).
Statistical analysis
Data were expressed as mean ± SD. One way-ANOVA.
When more than two groups were involved in analysis,
Dunnett test was used for comparison of difference be-
tween two groups. Comparisons with p <0.05 were con-
sidered statistically significant. Comparisons with p <0.05
were considered statistically significant.
Additional files
Additional file 1: Supplemental materials and methods.
Additional file 2: Figure S1. Nur77 inhibits DC-specific marker CD209
changes in oxLDL-treated RAW264.7 cells. (A) RAW264.7 cells stably expressing
GFP, GFP-Nur77, GFP-Nur77-ΔTAD or GFP-Nur77-ΔDBD were treated with
oxLDL (10 μg/ml) for 48 h and visualized by fluorescent microscopy (200×).
Results are representative of three separate experiments. (B) Cells with CD209
positive staining were calculated as the percentage of all cells observed in 10
different fields at 200× magnification. The bars represent mean ± SD from
three experiments. *p <0.05 compared with GFP-expressing control cells.
Abbreviations
oxLDL: Oxidized LDL; DC: Dendritic cells; DBD: DNA-binding domain;
GFP-Nur77: GFP fusions with either full-length Nur77; GFP-Nur77-ΔDBD: Nur77
lacking the DNA binding domain; GFP-Nur77-ΔTAD: Nur77 lacking the
transactivation domain; VEGF: Vascular endothelial growth factor.
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